

June 30, 2004
AnGes MG, Inc.

AnGes MG to Join the University of Tokyo (Hospital) Project:

"22nd Century Medical Center" (tentative name)

-Establishes joint research program on forefront clinical medicine, including development of genetic medication and cell remediation medicines.-

AnGes MG hereby officially announces its commitment to participation in the "22nd Century Medical Center " project of the University of Tokyo Hospital.

This decision will enable AnGes MG to hold free courses at the 22nd Century Medical Center, which is scheduled to be inaugurated in the year 2006 by the University of Tokyo Hospital, to develop new therapies for cardiovascular disorders_using genetic and cell remediation medications_and to conduct clinical studies on new treatments.

AnGes MG is a so-called university spin out venture founded in 1999 when a business entity was needed to market the R&D fruits from Osaka University Graduate School of Medicine.

The business is based on three seed technologies related to genetic medicines and efforts are being made now to put them into practical use and market them through an industrial-academic cooperation with the Osaka University Graduate School of Medicine. As for new technologies to be developed in the future, AnGes MG has been reviewing and assessing the research results of universities nationwide for their eventual commercialization.

The 22nd Century Medical Center project, which has accepted the participation of AnGes MG, is a facility to be inaugurated in the course of fiscal 2006 by the University of Tokyo Hospital as a future hub for industrial and academic medical research in Japan. As national universities have been turned into independent administrative entities by the new law put into effect this year, research conducted by universities will need to have more commercial significance in addition to its academic value. Therefore, industry-related clinical medicine at the 22nd Century Medical Center will also be the subject of studies and with the commencement of free courses by private enterprises, the research outcomes of industrial-academic cooperation will move closer to the commercial end of the spectrum.

AnGes MG has been making progress in the development of new genetic medicines in the field of cardiovascular and circulatory disorders, and with its participation in the 22nd Century Medical Center project, major achievements in cutting-edge therapies are expected. Cooperation with leading medical entities such as the University of Tokyo Hospital and the Tokyo University Faculty of Medicine will also become possible, fueling expectations for the research of new therapies as genetic and cell remediation therapies in the field of cardiovascular disorders.

With its participation in the project, AnGes MG hopes to dramatically increase its opportunities for securing and commercializing new seed technologies.